Surface Oncology’s SRF231 Granted Orphan Drug Status for Treatment of Multiple Myeloma
SRF231, an experimental anti-CD47 immunotherapy candidate developed by Surface Oncology, was granted orphan drug status by the U.S. Food and Drug Administration for…
